PARP1 and cancer: Given the widespread clinical use of inhibitors targeting oncogenic kinases, particularly RTKs, which tend to exhibit a more pronounced therapeutic window between normal and cancer cells (14, 15), we undertook an investigation into the involvement of RTKs in PARP trapping and their potential as agents for overcoming PARPi resistance.